- Disease
- Monday, 04 May 2020
Targovax Releases Update for Mesothelioma Trial Combining ONCOS-102 and Chemotherapy
The trial is an open label, randomized, exploratory phase I/II trial adding ONCOS-102 to standard of care (SoC) chemotherapy (pemetrexed/cisplatin) in first and second (and later) line mesothelioma to assess safety, immune activation and clinical efficacy. In total, 31 patients have been enrolled with 20 patients in the experimental group receiving the ONCOS-102 and SoC, and 11 patients in a control group receiving SoC only. The first set of data was reported in January 2020, see link to press release here.
All patients have now completed the 9-month follow-up. The median Progression Free Survival (mPFS) remains in line with previously published data and compares favorably with historical control. The first line patients continue to perform well, and will be the population prioritized for future development. The updated PFS data are being complemented by biomarker analyses and early data demonstrate enhanced immune activation and modulation of tumor microenvironment in ONCOS-102-treated patients compared to the control group. 12-months clinical data as well as more extensive immune activation and biomarker data will be released in the middle of 2020.
Dr. Magnus Jäderberg, Chief Medical Officer of Targovax, said: "We are very pleased to see the encouraging early PFS figures holding up in the 9-month analysis. The data look particularly promising for first line patients, and the preparations for a subsequent checkpoint inhibitor combination trial in this population with a big pharma collaboration partner are progressing according to plan."
Related Industry Updates
CDC says, Hantavirus isn't a global public health threat
Mar 25, 2020
Top Human Capital Trends Fueling Workplace Innovation
May 20, 2020
Majority of the U.S. firms in China see revenue hit from coronavirus: AmCham survey
Feb 07, 2020
Critical Access Hospital Transitional Care: An essential partnership and pathway for Acute Care Hospitals to create desperately needed capacity during COVID-19 Pandemic
Mar 19, 2020
Industries That will Withstand the COVID-19 Storm
Mar 30, 2020
BioGX and Bosch Healthcare Solutions announce partnership to develop Infectious disease tests for the Vivalytic platform
May 27, 2020
Young Investigators awarded $200k to study how the body’s own defense mechanisms may be used in the fight against lung cancer
Dec 06, 2019